INTRODUCTION: Studies examining the efficacy of tobacco dependence treatment among recovering alcoholic smokers have produced mixed findings. We set out to investigate this issue further by conducting a randomized, double-blind, placebo-controlled trial of bupropion sustained-release (SR) for smoking relapse prevention among abstinent alcoholic smokers. METHODS:Participants (N = 195) met DSM-IV criteria for a history of alcohol abuse or dependence and had at least 1 year of continuous abstinence from alcohol and drugs. Open-label treatment with nicotine patch therapy was provided to all subjects for 8 weeks. The initial nicotine patch dose was determined by the subject's baseline serum cotinine concentration with an aim to achieve 100% cotinine replacement. All subjects who were confirmed abstinent from smoking throughout the final week of nicotine patch therapy (Week 8) were randomly assigned to receive bupropion SR 300 mg/day or placebo through Week 52. RESULTS:A total of 110 participants were randomized to the double-blind treatment. No significant difference was observed between the bupropion and placebo groups for rates of continuous smoking abstinence, 41.1% (95% CI = 28.1%-55.0%) versus 40.7% (95% CI = 27.6%-55.0%), respectively, p = 1.0, or point prevalence abstinence, 39.3% (95% CI = 26.5%-53.3%) versus 40.7% (95% CI = 27.6%-55.0%), respectively, p = 1.0, at the end of the treatment (Week 52). Relapse to alcohol occurred in 4% of subjects (n = 4) during the study. DISCUSSION: Treatment with bupropion SR among abstinent alcoholic smokers did not delay relapse or result in improved long-term smoking abstinence.
RCT Entities:
INTRODUCTION: Studies examining the efficacy of tobacco dependence treatment among recovering alcoholic smokers have produced mixed findings. We set out to investigate this issue further by conducting a randomized, double-blind, placebo-controlled trial of bupropion sustained-release (SR) for smoking relapse prevention among abstinent alcoholic smokers. METHODS:Participants (N = 195) met DSM-IV criteria for a history of alcohol abuse or dependence and had at least 1 year of continuous abstinence from alcohol and drugs. Open-label treatment with nicotine patch therapy was provided to all subjects for 8 weeks. The initial nicotine patch dose was determined by the subject's baseline serum cotinine concentration with an aim to achieve 100% cotinine replacement. All subjects who were confirmed abstinent from smoking throughout the final week of nicotine patch therapy (Week 8) were randomly assigned to receive bupropion SR 300 mg/day or placebo through Week 52. RESULTS: A total of 110 participants were randomized to the double-blind treatment. No significant difference was observed between the bupropion and placebo groups for rates of continuous smoking abstinence, 41.1% (95% CI = 28.1%-55.0%) versus 40.7% (95% CI = 27.6%-55.0%), respectively, p = 1.0, or point prevalence abstinence, 39.3% (95% CI = 26.5%-53.3%) versus 40.7% (95% CI = 27.6%-55.0%), respectively, p = 1.0, at the end of the treatment (Week 52). Relapse to alcohol occurred in 4% of subjects (n = 4) during the study. DISCUSSION: Treatment with bupropion SR among abstinent alcoholic smokers did not delay relapse or result in improved long-term smoking abstinence.
Authors: J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White Journal: Ann Intern Med Date: 2001-09-18 Impact factor: 25.391
Authors: Richard D Hurt; James E Krook; Ivana T Croghan; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; Carl G Kardinal; James A Knost; Maria Tria Tirona; Ferdinand Addo; Roscoe F Morton; John C Michalak; Paul L Schaefer; Patricia A Porter; Philip J Stella Journal: J Clin Oncol Date: 2003-03-01 Impact factor: 44.544
Authors: Brian Hitsman; George D Papandonatos; Dennis E McChargue; Andrew DeMott; María José Herrera; Bonnie Spring; Belinda Borrelli; Raymond Niaura Journal: Addiction Date: 2013-02 Impact factor: 6.526
Authors: Ryan T Hurt; Jon O Ebbert; Ivana T Croghan; Darrell R Schroeder; Richard D Hurt; J Taylor Hays Journal: Drug Alcohol Depend Date: 2018-01-02 Impact factor: 4.492
Authors: Jonathan Livingstone-Banks; Emma Norris; Jamie Hartmann-Boyce; Robert West; Martin Jarvis; Emma Chubb; Peter Hajek Journal: Cochrane Database Syst Rev Date: 2019-10-28
Authors: Jonathan Livingstone-Banks; Emma Norris; Jamie Hartmann-Boyce; Robert West; Martin Jarvis; Peter Hajek Journal: Cochrane Database Syst Rev Date: 2019-02-13